MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
For the six months, sales was USD 0.752 million compared to USD 41.47 million a year ago. Revenue was USD 65.3 million compared to USD 41.47 million a year ago. Net income was USD 45.31 million compared to net loss of USD 6.37 million a year ago. Basic earnings per share from continuing operations was USD 6.8 compared to basic loss per share from continuing operations of USD 0.96 a year ago.